Veraxa Biotech AG - Post de-SPAC

VRXANasdaq Switzerland Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$275.745 M

$1.95 +3.17%

Close of 21 Aug 2026

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

—

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Other share classes

Veraxa Biotech AG - Post de-SPAC lists more than one class of stock. Company figures above cover all classes combined.

VRXAW

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 503 →

#249Camp4 TherapeuticsCAMP$281.1M
#250Eledon PharmaceuticalsELDN$280.4M
#251Veraxa Biotech AG - Post de-SPACVRXA$275.7M
#252Whitehawk TherapeuticsWHWK$269.7M
#253AdageneADAG$265.5M

Where these numbers come from

Share counts and financials for Veraxa Biotech AG - Post de-SPAC are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 21 Aug 2026. Read the methodology.